{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Induction+Phase&page=21", "query": { "intervention": "Induction Phase", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 2297, "total_pages": 230, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Induction+Phase&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Induction+Phase&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T14:24:14.728Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00477035", "title": "Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Multiple Myeloma" ], "interventions": [ { "name": "CIK cells", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "bcnu", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "vinorelbine", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sally Arai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 22, "start_date": "2006-05", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2017-01-11", "last_synced_at": "2026-10-23T14:24:14.728Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00477035" }, { "nct_id": "NCT00148317", "title": "Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "liposomal doxorubicin", "type": "DRUG" }, { "name": "cyclophoshamide", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2005-06", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2017-07-18", "last_synced_at": "2026-10-23T14:24:14.728Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00148317" }, { "nct_id": "NCT02493868", "title": "A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Depressive Disorder, Treatment-Resistant" ], "interventions": [ { "name": "Esketamine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Duloxetine (Oral Antidepressant)", "type": "DRUG" }, { "name": "Escitalopram (Oral antidepressant)", "type": "DRUG" }, { "name": "Sertraline (Oral Antidepressant)", "type": "DRUG" }, { "name": "Venlafaxine Extended Release (XR) (Oral Antidepressant)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 719, "start_date": "2015-10-01", "completion_date": "2018-02-16", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-10-23T14:24:14.728Z", "location_count": 53, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02493868" }, { "nct_id": "NCT04383210", "title": "Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Solid Tumor", "Pancreatic Cancer", "Lung Cancer", "Head and Neck Cancer", "Breast Cancer", "Kidney Cancer", "Colorectal Cancer", "Bladder Cancer", "Ovarian Cancer", "Sarcoma", "Gallbladder Cancer", "Bile Duct Cancer", "Esophageal Cancer", "Uterine Cancer", "Cholangiocarcinoma", "Prostate Cancer" ], "interventions": [ { "name": "Seribantumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elevation Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2020-09-29", "completion_date": "2024-02-28", "has_results": true, "last_update_posted_date": "2025-04-03", "last_synced_at": "2026-10-23T14:24:14.728Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04383210" }, { "nct_id": "NCT04612725", "title": "A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "Benralizumab", "type": "BIOLOGICAL" }, { "name": "Placebo and Benralizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 159, "start_date": "2020-10-27", "completion_date": "2023-03-28", "has_results": true, "last_update_posted_date": "2024-03-13", "last_synced_at": "2026-10-23T14:24:14.728Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Mission Viejo, California + 8 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04612725" }, { "nct_id": "NCT01744223", "title": "Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myelogenous Leukemia", "Lymphoma", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "BPX-501 dose 1", "type": "BIOLOGICAL" }, { "name": "Rimiducid", "type": "DRUG" }, { "name": "BPX-501 dose 2", "type": "BIOLOGICAL" }, { "name": "BPX-501 dose 3", "type": "BIOLOGICAL" }, { "name": "BPX-501 dose 4", "type": "BIOLOGICAL" }, { "name": "SCT", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Bellicum Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 36, "start_date": "2013-03", "completion_date": "2032-10", "has_results": false, "last_update_posted_date": "2022-07-12", "last_synced_at": "2026-10-23T14:24:14.728Z", "location_count": 8, "location_summary": "Atlanta, Georgia • Buffalo, New York • New York, New York + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01744223" }, { "nct_id": "NCT00783692", "title": "Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "vedolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1116, "start_date": "2008-12", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2014-07-21", "last_synced_at": "2026-10-23T14:24:14.728Z", "location_count": 110, "location_summary": "Birmingham, Alabama • Los Angeles, California • Montebello, California + 91 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Montebello", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00783692" }, { "nct_id": "NCT01960387", "title": "Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Clofarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2013-10", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2016-08-02", "last_synced_at": "2026-10-23T14:24:14.728Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01960387" }, { "nct_id": "NCT00295165", "title": "Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "Sargramostim (Leukine)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2006-01", "completion_date": "2006-10", "has_results": false, "last_update_posted_date": "2013-12-04", "last_synced_at": "2026-10-23T14:24:14.728Z", "location_count": 47, "location_summary": "Huntsville, Alabama • Orange, California • San Francisco, California + 43 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Lakewood", "state": "Colorado" }, { "city": "Littleton", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00295165" }, { "nct_id": "NCT02015104", "title": "Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))", "type": "BIOLOGICAL" }, { "name": "PANVAC", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 32, "start_date": "2013-12-18", "completion_date": "2019-05-02", "has_results": true, "last_update_posted_date": "2025-07-01", "last_synced_at": "2026-10-23T14:24:14.728Z", "location_count": 2, "location_summary": "Bethesda, Maryland • New Brunswick, New Jersey", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02015104" } ] }